The core of the Company's technology is built around a unique recombinant human lactoferrin (rhLTF), a molecule having mammalian glycosylation. To our knowledge, this is the only rhLTF that is fully compatible with humans and currently available for preclinical testing. A novel fusion protein of hLTF with the Fc domain of IgG represents a natural extension of the Company’s portfolio of products for future clinical utility.
Copyright © 2018 PharmaReview Corporation - All Rights Reserved.